Evidence map›Paper›PMID 35549730›Full record

Trial reportDiabetes & vascular disease research

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.

Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Parkinson's disease and glucose metabolism impairment.Translational neurodegeneration · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wun-Zhih SiaoDivision of Cardiology, Department of Internal Medicine, 63276Chung Shan Medical University Hospital, Taichung, Taiwan.
Tsung-Kun LinDepartment of Pharmacy, 90989Taoyuan Armed Forces General Hospital, Taoyuan, Taiwan.
Jing-Yang HuangInstitute of Medicine, College of Medicine, 34899Chung Shan Medical University, Taichung, Taiwan.
Chin-Feng TsaiDivision of Cardiology, Department of Internal Medicine, 63276Chung Shan Medical University Hospital, Taichung, Taiwan.
Gwo-Ping JongDivision of Cardiology, Department of Internal Medicine, 63276Chung Shan Medical University Hospital, Taichung, Taiwan.ORCID 0000-0002-7786-5497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.

methodsThis is a population-based cohort study utilizing Taiwan's National Health Insurance Research Database. Each patient who took SGLT2 inhibitors was assigned to the SGLT2 inhibitor group, whereas 1:1 propensity score-matched randomly selected patients who were nonusers of SGLT2 inhibitors were assigned to the non-SGLT2 inhibitor group. The study outcome was incident dementia.

resultsA total of 976,972 patients newly diagnosed with type 2 diabetes mellitus (DM) between 2011 and 2018 were included in this study. After the patients' propensity score matching by age, sex, duration of DM, comorbidities and drug index date of the patients, a total of 103,247 patients in the SGLT2 inhibitor group and 103,247 in the non-SGLT2 inhibitor group were enrolled for analysis. The SGLT2 inhibitor group was associated with a lower risk of incident dementia (adjusted hazard ratio: 0.89, 95% confidence interval: 0.82-0.96;

conclusionsPatients with type 2 DM who were prescribed SGLT2 inhibitors were associated with a lower risk of incident dementia compared with those not prescribed SGLT2 inhibitors in real-world practice.

Indexed as

DementiaDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCohort StudiesGlucoseHumansLongitudinal StudiesRetrospective StudiesSodiumGlucoseSodiumSodium-Glucose Transporter 2 Inhibitorsdementiadiabetic complicationsSodium–glucose co-transporter inhibitorstype 2 diabetes

Identifiers

PMID35549730
PMCPMC9109279

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.